|
[1]HUNDAL R, SHAFFER EA.Gallbladder cancer:Epidemiology and outcome[J].Clin Epidemiol, 2014, 6 (1) :99-109.
|
|
[2]TORRE LA, SIEGEL RL, ISLAMI F, et al.Worldwide burden of and trends in mortality from gallbladder and other biliary tract cancers[J].Clin Gastroenterol Hepatol, 2018, 16 (3) :427-437.
|
|
[3]RAKIC'M, PATRLJ L, KOPLJAR M, et al.Current status and challenges in diagnosis and treatment of gallbladder cancer[J].Chin J Gen Surg, 2016, 25 (2) :157-161. (in Chineses) RAKIC'M, PATRLJ L, KOPLJAR M, 等.胆囊癌的临床诊疗现状与挑战[J].中国普通外科杂志, 2016, 25 (2) :157-161.
|
|
[4]ZHAO YH, JIA YJ, DONG CC, et al.Study on protective effect of Yigan Jiangzhi recipe on early alcoholic liver injury[J].Tianjin JTradit Chin Med, 2010, 27 (3) :265. (in Chineses) 赵远红, 贾英杰, 董承超, 等.益肝降脂方预处理对早期酒精性肝损伤的保护作用研究[J].天津中医药, 2010, 27 (3) :265.
|
|
[5]DEEKS ED.Olaparib:First global approval[J].Drugs, 2015, 75 (2) :231-240.
|
|
[6]FAN B, WU YM.PARP inhibitors-application of olapani in the treatment of ovarian cancer[J].Beijing Med J, 2016, 38 (11) :1206-1209. (in Chinese) 樊蓓, 吴玉梅.PARP抑制剂---奥拉帕尼应用于卵巢癌治疗的研究进展[J].北京医学, 2016, 38 (11) :1206-1209.
|
|
[7]TANG YN, JIN L, SUN CR.Olaparib:A new drug for hereditary ovarian cancer treatment[J].J Pharm Pract, 2015, 33 (4) :373-375. (in Chinese) 唐跃年, 金樑, 孙朝荣.治疗遗传性卵巢癌的新药-奥拉帕尼[J].药学实践杂志, 2015, 33 (4) :373-375.
|
|
[8]LIU Y, PENG YP, CHU X, et al.The role of ATM-mediated DNA repair in tumor radiotherapy[J].Chin J Gen Pract, 2016, 14 (3) :468-470. (in Chinese) 刘宇, 彭莹鹏, 楚溪, 等.ATM介导DNA修复在肿瘤放疗中的作用[J].中华全科医学, 2016, 14 (3) :468-470.
|
DownLoad: